Gallbladder cancer is rare but aggressive, with the American Cancer Society projecting about 12,640 new cases and 4,590 deaths for 2026. Because the organ sits hidden beneath the liver, early disease is typically asymptomatic, and only about 10% of patients present with early-stage, resectable disease; roughly half of all cases are instead discovered incidentally during cholecystectomy for presumed benign disease. With patients 65 and older accounting for about two-thirds of diagnoses, recognizing suspicious imaging findings and documenting disease status precisely are among the highest-value clinical actions a primary care team can take.
AAVBC's Gallbladder Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across primary and metastatic biliary tract disease, HCC/RAF V28 mapping, diagnostic thresholds aligned to NCCN v1.2026 and AJCC 8th-edition TNM staging, MEAT documentation standards, NCCN-aligned treatment escalation by stage, geriatric risk-factor screening, and referral and follow-up timing. Grounded in current NCCN Biliary Tract Cancers guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize suspicious gallbladder findings before the window for curative resection closes, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of gallbladder cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Gallbladder cancer is rare but aggressive, with the American Cancer Society projecting about 12,640 new cases and 4,590 deaths for 2026. Because the organ sits hidden beneath the liver, early disease is typically asymptomatic, and only about 10% of patients present with early-stage, resectable disease; roughly half of all cases are instead discovered incidentally during cholecystectomy for presumed benign disease. With patients 65 and older accounting for about two-thirds of diagnoses, recognizing suspicious imaging findings and documenting disease status precisely are among the highest-value clinical actions a primary care team can take.
AAVBC's Gallbladder Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across primary and metastatic biliary tract disease, HCC/RAF V28 mapping, diagnostic thresholds aligned to NCCN v1.2026 and AJCC 8th-edition TNM staging, MEAT documentation standards, NCCN-aligned treatment escalation by stage, geriatric risk-factor screening, and referral and follow-up timing. Grounded in current NCCN Biliary Tract Cancers guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize suspicious gallbladder findings before the window for curative resection closes, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of gallbladder cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
